Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Clinical trial NCT04531982 · COMPLETED
Trial details
- NCT number
- NCT04531982
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-05
- Primary completion
- 2024-01-25
- Enrollment
- 454
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.